#ESMODailyReporter🔗
LightNews LightNews
myesmo.bsky.social
#ESMO25: Updated analyses from the NADINA and SWOG S1801 #ClinicalTrials confirm the sustained benefits of neoadjuvant immune checkpoint inhibition (#ICI) in patients with resectable stage III or IV melanoma.
#ESMODailyReporter 🔗https://ow.ly/SuVX50XjKk7

#immunotherapy
November 4, 2025 at 3:10 PM
myesmo.bsky.social
#ESMO25: #Immunotherapy plus TIGIT inhibitor fails to show benefit over standard of care in the SKYSCRAPER-03 #ClinicalTrial, while induction immunochemotherapy shows promise in unresectable #NSCLC.
#ESMODailyReporter 🔗https://ow.ly/RiBl50XjIO0

#LungCancer
November 4, 2025 at 11:05 AM
myesmo.bsky.social
#ESMO25: Early results with two novel #immunotherapies in advanced neuroendocrine carcinoma (#NEC) suggest greater efficacy versus chemotherapy alone but with higher toxicity #ESMODailyReporter 🔗 https://ow.ly/I4x150XjCwR

#RareCancers
November 3, 2025 at 11:15 AM
myesmo.bsky.social
#ESMO25: Positive efficacy results without safety concerns seen with NW-301V, a TCR-T therapy targeting KRAS G12V, in patients with KRAS G12V-mutant advanced #GICancer in a phase I #ClinicalTrial.
#ESMODailyReporter🔗 https://ow.ly/jouK50XjATp


Jon Lim, MRCP PhD
October 30, 2025 at 4:30 PM
myesmo.bsky.social
#ESMO25: Overall survival was significantly improved with zanzalintinib, a multitargeted #TKI, plus atezolizumab vs regorafenib in patients with previously treated metastatic colorectal cancer (#mCRC) in the STELLAR-303 trial.
#ESMODailyReporter🔗 https://ow.ly/xAhR50XilSJ
October 29, 2025 at 9:30 AM
myesmo.bsky.social
#ESMO25: A trend toward improved progression-free survival was observed with the IO102-IO103 #CancerVaccine plus pembrolizumab vs pembrolizumab alone in the IOB-013/KN-D18 phase III #ClinicalTrial in untreated advanced #melanoma.
#ESMODailyReporter🔗 https://ow.ly/QxxW50XijYT
October 28, 2025 at 4:10 PM
myesmo.bsky.social
#ESMO25: #ctDNA has emerged as a clinically actionable #biomarker to guide #EGFR rechallenge in metastatic #ColorectalCancer. Guillermo Argilés Martinez discusses positive #ClinicalTrial data with this selective approach.
#ESMODailyReporter 🔗 https://ow.ly/lnKi50Xiei7
October 27, 2025 at 4:02 PM
myesmo.bsky.social
#ESMO25: Early data with two novel antibody–drug conjugates demonstrate pan-tumour activity in a diverse range of advanced cancers, with tumour reductions in heavily pre-treated patients #ESMODailyReporter 🔗 https://ow.ly/UIxb50XgnGI

#TranslationalResearch
October 24, 2025 at 2:15 PM
myesmo.bsky.social
#ESMO25: Data from phase III #ClinicalTrials with a novel combination (fuzuloparib with apatinib) and with weekly paclitaxel highlight benefits for patient subgroups with #OvarianCancer #ESMODailyReporter 🔗 https://ow.ly/wkMn50Xgo2y

#GynaecologicCancer
October 24, 2025 at 11:45 AM
myesmo.bsky.social
#ESMO25: OS was significantly improved w/ the #ADC disitamab vedotin plus #immunotherapy w/ toripalimab vs chemotherapy in first-line advanced HER2-expressing #UrothelialCarcinoma in the RC48-C016 #ClinicalTrial.
#ESMODailyReporter 🔗 https://ow.ly/ZS9V50XeAsN

October 19, 2025 at 4:15 PM
myesmo.bsky.social
#ESMO25: First-line ivonescimab, a bispecific antibody targeting PD-1 and VEGF, plus chemotherapy improved progression-free survival vs tislelizumab plus chemotherapy in patients with squamous #NSCLC in the phase III HARMONi-6 trial.
#ESMODailyReporter 🔗 https://ow.ly/wl7X50XeA1o

October 19, 2025 at 2:45 PM
myesmo.bsky.social
#ESMO25: #CancerVaccines may be approaching prime time after decades of missed promises. @DoniaMarco discusses how connecting the dots between advances in major areas of vaccine research could deliver a long-promised breakthrough.
#ESMODailyReporter 🔗 https://ow.ly/rWB250XeyHs

October 19, 2025 at 10:30 AM
myesmo.bsky.social
Results were presented at #ESMO25 from phase III #ClinicalTrials that highlighted both progress and ongoing challenges in the treatment of HER2-positive upper #GICancers.
Read more in the #ESMODailyReporter 🔗 https://ow.ly/SF7J50Xe3nK

October 17, 2025 at 1:25 PM
myesmo.bsky.social
#ESMO25: Lifetime Achievement Award recognises Rolf Stahel’s visionary leadership and enduring contributions to oncology, which have shaped research, education and international collaboration. More on his outstanding work.
#ESMODailyReporter 🔗 https://ow.ly/YMvx50XcYBP
October 17, 2025 at 11:45 AM
myesmo.bsky.social
#ESMO25: The 2025 ESMO Award for Translational Research recognises Christina Curtis groundbreaking contributions to cancer genomics and her pioneering role in translating complex data science into clinically meaningful insights
#ESMODailyReporter🔗 https://ow.ly/vY9R50XcXVV

October 17, 2025 at 10:45 AM
myesmo.bsky.social
Thierry Conroy receives the #ESMO25 Award in recognition of his remarkable contributions, particularly to the development of FOLFIRINOX for #PancreaticCancer and #RectalCancer and validation of #QoL assessment tools.
Read more in the #ESMODailyReporter 🔗 https://ow.ly/6HO850XcXO2
October 17, 2025 at 10:25 AM
myesmo.bsky.social
🤖 What is the #EnvironmentalCost of #ArtificialIntelligence?

In his latest #ESMODailyReporter column, @pawelsobczuk.bsky.social discusses how the widespread use of AI tools is associated with high demand for energy, water & minerals.

🔗 buff.ly/VatevRB

#AIOncology #HealthAI #HealthData
September 25, 2025 at 2:01 PM
myesmo.bsky.social
#MAP2025: Umberto Malapelle describes how new technologies – #multiomic spatial profiling, #ctDNA analysis and #AI – can be integrated for a deeper understanding of cancer complexity.

Read more in the #ESMODailyReporter.

🔗 buff.ly/b26Mre7
Integrating multiomic spatial profiling and ctDNA for a deeper understanding of cancer complexity
Diverse approaches are investigated in oncology that also include the use of artificial intelligence
buff.ly
September 16, 2025 at 12:10 PM
myesmo.bsky.social
#MAP2025: Two studies highlight T-cell dysfunction in pre-cancerous lesions, supporting targeted immune interception as a novel #immunotherapy approach.

Read more in the #ESMODailyReporter #TranslationalResearch

🔗 buff.ly/BKFC2yU
Immune interception represents an exciting opportunity to stop cancer in its tracks
Data from two studies suggest a good rationale for targeting T-cell dysfunction with precision immunotherapy to intercept pre-cancerous lesions
buff.ly
September 16, 2025 at 11:05 AM
myesmo.bsky.social
Epigenetic analyses provide valuable insights into early cachexia detection in #glioma and #OvarianCancer evolution after #NeoadjuvantChemotherapy as presented at #MAP2025.

Read more in the #ESMODailyReporter:
🔗 buff.ly/QBmPzJl
September 15, 2025 at 2:23 PM
myesmo.bsky.social
🤖 In the #ESMODailyReporter Charles Ferté discusses how AI and digital tools may play a crucial role in integrating the patient experience into the continuum of cancer care.

🔗 buff.ly/eVjxA8c

#AIOncology #HealthAI #HealthData #AIForPatients #PatientCare #ESMOAI25
August 29, 2025 at 12:30 PM
myesmo.bsky.social
🤖 Will AI reduce or increase inequities in cancer care?

In his latest #ESMODailyReporter column, Dario Trapani explores how ethical risks and uneven access to AI in oncology may leave some patients behind.

🔗 buff.ly/49mWioA

#AIOncology #HealthAI #HealthData
August 13, 2025 at 12:30 PM
myesmo.bsky.social
How does #ESMOMCBS v2.0 reflect the evolving #oncology treatment landscape and the priorities of #PatientsWithCancer? Sjoukje Oosting shares her insights in the #ESMODailyReporter.
🔗 ow.ly/8aJt50WBROf
August 8, 2025 at 7:55 AM
myesmo.bsky.social
Novel approaches are being tested to overcome current challenges in the use of #CellularTherapies such as high #toxicity and a complex manufacturing process. #CancerResearch #CARTcells
Read the opinion by Philippe Cassier in the #ESMODailyReporter
🔗 buff.ly/rersLJ6
August 7, 2025 at 8:06 AM
myesmo.bsky.social
In a study published in the ESMO Real World Data and Digital Oncology, a #MachineLearning approach outperformed #cancer-specific models and revealed universal #biomarkers to guide #EndOfLifeCare decisions.

Read the analysis by @rdienstmann.bsky.social in the #ESMODailyReporter.

🔗 buff.ly/lNeReKH
July 31, 2025 at 1:03 PM